Glaukos Corporation (NYSE:GKOS) Receiving Somewhat Favorable Media Coverage, Analysis Finds
News headlines about Glaukos Corporation (NYSE:GKOS) have been trending somewhat positive on Sunday, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Glaukos Corporation earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.9435848486247 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Chartists Place Glaukos Corp (GKOS) on Notice: Technical Update … – Evergreen Caller (evergreencaller.com)
- Glaukos Corporation (NYSE:GKOS) Sees Unusual Trading Volume in Its Shares – Modern Readers (modernreaders.com)
- See what the IHS Markit Score report has to say about Glaukos Corp. (finance.yahoo.com)
- Zacks Investment Research Lowers Glaukos Corporation (GKOS) to Hold (americanbankingnews.com)
- Abbott Laboratories (ABT) registers a price change of 0.20% while Glaukos Corporation (GKOS) finishes with a flow of … – Stocks Gallery (stocksgallery.com)
Glaukos Corporation (NYSE:GKOS) opened at 37.50 on Friday. Glaukos Corporation has a 12-month low of $28.26 and a 12-month high of $52.49. The firm’s 50-day moving average is $40.38 and its 200 day moving average is $43.21. The firm’s market cap is $1.29 billion.
Several equities research analysts recently weighed in on GKOS shares. Stephens raised shares of Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research note on Monday, May 8th. Zacks Investment Research downgraded shares of Glaukos Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. BidaskClub raised shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. TheStreet downgraded shares of Glaukos Corporation from a “c” rating to a “d+” rating in a research note on Wednesday, May 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $54.00 target price on shares of Glaukos Corporation in a research note on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $52.33.
COPYRIGHT VIOLATION WARNING: “Glaukos Corporation (NYSE:GKOS) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/glaukos-corporation-nysegkos-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.